Company profile
RELMADA THERAPEUTICS, INC.
NASDAQ:RLMDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ESMETHADONE | phase3 | — | 6 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07313891 | phase3 | withdrawn | 2026-05-01 | 2029-09-01 | Relmada Therapeutics, Inc. | A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT |
| NCT07464145 | phase3 | not_yet_recruiting | 2027-02-01 | 2029-12-01 | Relmada Therapeutics, Inc. | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer |
| NCT07342517 | phase3 | withdrawn | 2026-06-30 | 2027-06-30 | Relmada Therapeutics, Inc. | A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy |
| NCT04688164 | phase3 | completed | 2021-01-08 | 2022-11-01 | Relmada Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) |
| NCT05081167 | phase3 | completed | 2021-06-02 | 2022-09-13 | Relmada Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) |
FDA applications (0)
No records yet.